Data / Form D filings / Edesa Biotech, Inc.
Edesa Biotech, Inc.: Form D filings
Edesa Biotech, Inc., a biotechnology company in Markham, Ontario, Canada, filed 9 Form D notices with the SEC between 2012 and 2026. The latest, on June 26, 2026, reports $3.5 million sold of a $3.5 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 100 SPY COURT, Markham, Ontario, Canada, L3R 5
- Phone
- (289) 800-9600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1540159
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | New notice | $3,500,000 | $3,499,986 | $14 | 4 | Jun 16, 2026 | sec.gov |
| Feb 14, 2025 | New notice | $15,000,000 | $15,000,000 | 15 | Feb 12, 2025 | sec.gov | |
| Apr 5, 2022 | New notice | Indefinite | $0 | 1 | Mar 21, 2022 | sec.gov | |
| Jul 21, 2016 | New notice | $6,750,000 | $6,750,000 | 4 | Jul 6, 2016 | sec.gov | |
| Oct 3, 2013 | Amendment | $12,000,000 | $12,000,000 | 50 | Sep 9, 2013 | sec.gov | |
| Sep 3, 2013 | New notice | $12,000,000 | $0 | $12,000,000 | 0 | Yet to occur | sec.gov |
| Apr 11, 2013 | New notice | $1,613,700 | $1,613,700 | 22 | Apr 3, 2013 | sec.gov | |
| Jan 15, 2013 | New notice | $505,000 | $504,596 | $404 | 9 | Jan 2, 2013 | sec.gov |
| Oct 31, 2012 | New notice | $1,005,800 | $1,005,800 | 3 | Oct 25, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Sean MacDonald | Director | |
| Pardeep Nijhawan | Executive Officer, Director | |
| Carlo Sistilli | Director | |
| Michael Brooks | Executive Officer | |
| Peter Weiler | Executive Officer | |
| Joan Chypyha | Director | |
| Charles Olson | Director | |
| Patrick Marshall | Director | |
| David Liu | Director |
Every Form D from the week of Jun 22, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Edesa Biotech, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.